Jincheng Pharma advances VGX-3100 trial for vaginal precancer

Shandong Jincheng Pharmaceutical Group (SZSE:300233) announced that Beijing Orient Gene Biotech, in which it holds a stake, has received approval from China's National Medical Products Administration (NMPA) for its VGX-3100 clinical trial application. The Phase II trial will evaluate VGX-3100, developed in collaboration with Inovio, for treating HPV-16/18 related vaginal precancerous lesions. VGX-3100, already in Phase III trials for cervical precancer and Phase II for anal precancer, aims to eliminate HPV and restore affected tissue. The company highlights that there are currently no targeted therapies for vaginal precancerous lesions in clinical development in China. While this advancement is positive, the company cautions that the trial's timeline and outcomes remain uncertain. The announcement emphasizes that this development is not expected to significantly impact Jincheng Pharmaceutical's near-term financial performance.